Potentiation of adriamycin cytotoxicity by dipyridamole against hela cells in vitro and sarcoma 180 cells in vivo

Hiroki Kusumoto, Yoshihiko Maehara, Hideaki Anai, Tetsuya Kusumoto, Keizo Sugimachi

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

Dipyridamole (DP) is clinically prescribed for its vasodilating and antiplatelet effects. DP also inhibits nucleoside transport and enhances cytostatic activity of antimetabolites. We obtained evidence for augmentation of the cytocidal effect of Adriamycin (ADM) by DP, both in vitro and in vivo. Nontoxic levels of DP enhanced the cytotoxicity of ADM against HeLa cells, and the 50% effective concentration of ADM was decreased 2.4-fold by DP. DP also increased the activity of ADM in clonogenic assays. Intracellular levels of ADM in the case of concomitant exposure to ADM and DP were 1.5-fold higher than in the case of exposure to ADM alone, determined using high-performance liquid chromatography. Incorporation of ADM into the cells pretreated with DP was also increased (1.4-fold), while the efflux was little affected. The growth of Sarcoma 180 tumors was prominently suppressed by the combination of ADM and DP, compared to findings with ADM alone. DP also prolonged the survival of Sarcoma 180 tumor-bearing mice, when given in combination with ADM. While the enhancement of cytostatic activity of antimetabolites has been attributed to a decrease in utilization of the salvage pathway by DP, our data show that the synergic effects of DP with ADM were the result of increased intracellular levels of ADM.

Original languageEnglish
Pages (from-to)1208-1212
Number of pages5
JournalCancer Research
Volume48
Issue number5
Publication statusPublished - Jan 1 1988

Fingerprint

Sarcoma 180
Dipyridamole
HeLa Cells
Doxorubicin
Antimetabolites
Cytostatic Agents
In Vitro Techniques
Nucleosides

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Kusumoto, H., Maehara, Y., Anai, H., Kusumoto, T., & Sugimachi, K. (1988). Potentiation of adriamycin cytotoxicity by dipyridamole against hela cells in vitro and sarcoma 180 cells in vivo. Cancer Research, 48(5), 1208-1212.

Potentiation of adriamycin cytotoxicity by dipyridamole against hela cells in vitro and sarcoma 180 cells in vivo. / Kusumoto, Hiroki; Maehara, Yoshihiko; Anai, Hideaki; Kusumoto, Tetsuya; Sugimachi, Keizo.

In: Cancer Research, Vol. 48, No. 5, 01.01.1988, p. 1208-1212.

Research output: Contribution to journalArticle

Kusumoto, H, Maehara, Y, Anai, H, Kusumoto, T & Sugimachi, K 1988, 'Potentiation of adriamycin cytotoxicity by dipyridamole against hela cells in vitro and sarcoma 180 cells in vivo', Cancer Research, vol. 48, no. 5, pp. 1208-1212.
Kusumoto H, Maehara Y, Anai H, Kusumoto T, Sugimachi K. Potentiation of adriamycin cytotoxicity by dipyridamole against hela cells in vitro and sarcoma 180 cells in vivo. Cancer Research. 1988 Jan 1;48(5):1208-1212.
Kusumoto, Hiroki ; Maehara, Yoshihiko ; Anai, Hideaki ; Kusumoto, Tetsuya ; Sugimachi, Keizo. / Potentiation of adriamycin cytotoxicity by dipyridamole against hela cells in vitro and sarcoma 180 cells in vivo. In: Cancer Research. 1988 ; Vol. 48, No. 5. pp. 1208-1212.
@article{ed171958d1204f508ba2f00c5932c781,
title = "Potentiation of adriamycin cytotoxicity by dipyridamole against hela cells in vitro and sarcoma 180 cells in vivo",
abstract = "Dipyridamole (DP) is clinically prescribed for its vasodilating and antiplatelet effects. DP also inhibits nucleoside transport and enhances cytostatic activity of antimetabolites. We obtained evidence for augmentation of the cytocidal effect of Adriamycin (ADM) by DP, both in vitro and in vivo. Nontoxic levels of DP enhanced the cytotoxicity of ADM against HeLa cells, and the 50{\%} effective concentration of ADM was decreased 2.4-fold by DP. DP also increased the activity of ADM in clonogenic assays. Intracellular levels of ADM in the case of concomitant exposure to ADM and DP were 1.5-fold higher than in the case of exposure to ADM alone, determined using high-performance liquid chromatography. Incorporation of ADM into the cells pretreated with DP was also increased (1.4-fold), while the efflux was little affected. The growth of Sarcoma 180 tumors was prominently suppressed by the combination of ADM and DP, compared to findings with ADM alone. DP also prolonged the survival of Sarcoma 180 tumor-bearing mice, when given in combination with ADM. While the enhancement of cytostatic activity of antimetabolites has been attributed to a decrease in utilization of the salvage pathway by DP, our data show that the synergic effects of DP with ADM were the result of increased intracellular levels of ADM.",
author = "Hiroki Kusumoto and Yoshihiko Maehara and Hideaki Anai and Tetsuya Kusumoto and Keizo Sugimachi",
year = "1988",
month = "1",
day = "1",
language = "English",
volume = "48",
pages = "1208--1212",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "5",

}

TY - JOUR

T1 - Potentiation of adriamycin cytotoxicity by dipyridamole against hela cells in vitro and sarcoma 180 cells in vivo

AU - Kusumoto, Hiroki

AU - Maehara, Yoshihiko

AU - Anai, Hideaki

AU - Kusumoto, Tetsuya

AU - Sugimachi, Keizo

PY - 1988/1/1

Y1 - 1988/1/1

N2 - Dipyridamole (DP) is clinically prescribed for its vasodilating and antiplatelet effects. DP also inhibits nucleoside transport and enhances cytostatic activity of antimetabolites. We obtained evidence for augmentation of the cytocidal effect of Adriamycin (ADM) by DP, both in vitro and in vivo. Nontoxic levels of DP enhanced the cytotoxicity of ADM against HeLa cells, and the 50% effective concentration of ADM was decreased 2.4-fold by DP. DP also increased the activity of ADM in clonogenic assays. Intracellular levels of ADM in the case of concomitant exposure to ADM and DP were 1.5-fold higher than in the case of exposure to ADM alone, determined using high-performance liquid chromatography. Incorporation of ADM into the cells pretreated with DP was also increased (1.4-fold), while the efflux was little affected. The growth of Sarcoma 180 tumors was prominently suppressed by the combination of ADM and DP, compared to findings with ADM alone. DP also prolonged the survival of Sarcoma 180 tumor-bearing mice, when given in combination with ADM. While the enhancement of cytostatic activity of antimetabolites has been attributed to a decrease in utilization of the salvage pathway by DP, our data show that the synergic effects of DP with ADM were the result of increased intracellular levels of ADM.

AB - Dipyridamole (DP) is clinically prescribed for its vasodilating and antiplatelet effects. DP also inhibits nucleoside transport and enhances cytostatic activity of antimetabolites. We obtained evidence for augmentation of the cytocidal effect of Adriamycin (ADM) by DP, both in vitro and in vivo. Nontoxic levels of DP enhanced the cytotoxicity of ADM against HeLa cells, and the 50% effective concentration of ADM was decreased 2.4-fold by DP. DP also increased the activity of ADM in clonogenic assays. Intracellular levels of ADM in the case of concomitant exposure to ADM and DP were 1.5-fold higher than in the case of exposure to ADM alone, determined using high-performance liquid chromatography. Incorporation of ADM into the cells pretreated with DP was also increased (1.4-fold), while the efflux was little affected. The growth of Sarcoma 180 tumors was prominently suppressed by the combination of ADM and DP, compared to findings with ADM alone. DP also prolonged the survival of Sarcoma 180 tumor-bearing mice, when given in combination with ADM. While the enhancement of cytostatic activity of antimetabolites has been attributed to a decrease in utilization of the salvage pathway by DP, our data show that the synergic effects of DP with ADM were the result of increased intracellular levels of ADM.

UR - http://www.scopus.com/inward/record.url?scp=0023839101&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023839101&partnerID=8YFLogxK

M3 - Article

C2 - 3342401

AN - SCOPUS:0023839101

VL - 48

SP - 1208

EP - 1212

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 5

ER -